Regeneron Invests $150 Million In Tessera To Advance One-Time Gene Therapy For Rare Genetic Disorder

benzinga.com/news/health-care/25/12/49142541/regeneron-invests-150-million-in-tessera-to-advance-one-time-gene-therapy-for-rare-genetic-disor

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., on Monday announced a global collaboration to develop and commercialize TSRA-196.
• REGN is lagging behind market performance. Stay ahead of the curve here.
TSRA-196 is Tessera’s lead investigational in vivo…

This story appeared on benzinga.com, 2025-12-01 17:35:48.
The Entire Business World on a Single Page. Free to Use →